Patrick Johan Hendrik Krol
Oprichter bij Aescap Life Sciences
Oorsprong van het eerstegraads netwerk van Patrick Johan Hendrik Krol
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector.
12
| Private Company | Investment Managers | 12 |
| Subsidiary | Pharmaceuticals: Major | 10 | |
F-Star Beta Ltd.
 F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
8
| Holding Company | Biotechnology | 8 |
F-star Biotechnology Ltd.
 F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.
6
| Subsidiary | Biotechnology | 6 |
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Aescap Life Sciences
1
| Mutual Fd-Open End | Investment Trusts/Mutual Funds | 1 |
Coöperatieve AESCAP Venture I UA
1
| Subsidiary | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Patrick Johan Hendrik Krol via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member Director/Board Member Chairman Director/Board Member Chairman Chief Executive Officer Chief Executive Officer Director/Board Member Director/Board Member Director of Finance/CFO | |
F-star Alpha Ltd.
 F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
F-Star Delta Ltd.
 F-Star Delta Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The company is based in Cambridge, UK and was founded in 2016. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Analyst | |
| Imperial College London | College/University | Doctorate Degree Graduate Degree | |
| University of Amsterdam | College/University | Graduate Degree Graduate Degree | |
| University of Leiden | College/University | Corporate Officer/Principal Graduate Degree | |
| INTELLIA THERAPEUTICS, INC. | Biotechnology | Founder Founder | |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Chairman Chief Executive Officer | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Founder Director/Board Member | |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Joint Polish Investment Fund Management BV
 Joint Polish Investment Fund Management BV Investment ManagersFinance Joint Polish Investment Fund Management BV (Joint Polish Investment Fund Management) is a venture capital firm founded in 2015. The firm headquartered in Netherlands. | Investment Managers | Chief Executive Officer Private Equity Investor | |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Abcuro, Inc.
 Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
Adnexus
 Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder President | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Founder Founder | |
| XENETIC BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
| Henley Management College | College/University | Masters Business Admin Masters Business Admin | |
| University of Aarhus | College/University | Doctorate Degree | |
NeoPhore Ltd.
 NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| University of Oxford | College/University | Doctorate Degree | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder | |
CatalYm GmbH
 CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
Synklino ApS
 Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | Medical/Nursing Services | Chairman | |
Danish Cancer Society
 Danish Cancer Society Miscellaneous Commercial ServicesCommercial Services The Danish Cancer Society provides support and resources for those affected by cancer, including patients and their families. The non-profit company is based in Copenhagen, Denmark and has subsidiaries in Denmark. The Danish company offers the latest information on patient involvement in cancer treatment and tools for utilizing patient-reported information. The organization also promotes cancer prevention through screening and works towards reducing the number of cancer cases and improving the quality of life for those who have survived cancer. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Chairman | |
DJS Antibodies Ltd.
 DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Director/Board Member | |
The University of Liverpool
 The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Doctorate Degree | |
Atlantic Healthcare Plc
 Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Pfizer Holdings International Luxembourg (PHIL) SARL
 Pfizer Holdings International Luxembourg (PHIL) SARL Financial ConglomeratesFinance Part of Pfizer Inc., Pfizer Holdings International Luxembourg (PHIL) SARL is an investment holding company. The company is based in Luxembourg, Luxembourg. | Financial Conglomerates | Corporate Officer/Principal | |
| AVACTA GROUP PLC | Miscellaneous Commercial Services | Chairman |
Statistieken
Internationaal
| Verenigd Koninkrijk | 16 |
| Verenigde Staten | 14 |
| Nederland | 7 |
| Denemarken | 6 |
| Oostenrijk | 3 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 10 |
| Commercial Services | 6 |
| Finance | 5 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 230 |
| Corporate Officer/Principal | 54 |
| Chairman | 47 |
| Independent Dir/Board Member | 41 |
| Chief Executive Officer | 40 |
Sterkste connecties
| Insiders | |
|---|---|
| Jean-Francois Formela | 48 |
| Nessan Bermingham | 36 |
| Eliot Forster | 35 |
| Edward Benz | 29 |
| Helmut Schühsler | 28 |
| Deborah Harland | 27 |
| Darlene Deptula-Hicks | 24 |
| Todd Brady | 20 |
| David Arkowitz | 20 |
| Pamela Klein | 19 |
| Hakan Goker | 18 |
| Geoff Race | 17 |
| John Blodgett Edwards | 17 |
| John Sørensen Haurum | 17 |
| Domenico Valerio | 15 |
- Beurs
- Insiders
- Patrick Johan Hendrik Krol
- Bedrijfsconnecties
